Tuesday, October 20, 2015

First case of cancer linked to Fukushima cleanup











The (very few) upsides to childhood illnesses











Johnson & Johnson's Stelara succeeds in Phase III Crohn's disease trial

(Reuters) - Johnson & Johnson's Stelara was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn's disease, according to data from a late stage trial, providing ammunition for a potential expanded approval of the medicine.









Eye drug setback hits Shire shares amid Baxalta pursuit

LONDON (Reuters) - Shares in Shire Plc fell 2 percent on Monday after the U.S. Food and Drug Administration (FDA) decided not to approve its most important pipeline medicine for dry eye disease and asked for more information.









Monday, October 12, 2015

The 10 warning signs of Alzheimer's

More than 5 million Americans are living with Alzheimer's today, with another person developing the disease every 68 seconds. By 2050, the number of people living with Alzheimer's disease is expected to triple.









Fighting back against Alzheimer's for 3 years